We have shown that B cell depletion therapy and/or immunosuppression therapy in patients with a range of autoimmune diseases is associated with significant changes in B cell repertoires reflecting different mechanisms of B cell modulation. However, the effect of different therapeutic interventions on B and T cell function and the resulting reconstitution is not well understood, particularly in relationship to patient prognosis. This project will apply single-cell genetic technologies to investigate the determinants of B and T cell persistence and reconstitution during and after therapy in autoimmune disease. This will be achieved through the development and application of novel experimental and computational approaches, working in partnership with a global network of clinicians, immunologists and sample cohorts.This information may be used to develop potential biomarkers of resistance to therapy and to determine potential therapeutic interventions that could be combined with the current standard of care that could target persistent clones in autoimmune diseases.
To investigate the determinants of B and T cell persistence and reconstitution during and after therapy in autoimmune disease and the association with outcome.
The DPhil will gain experience and training in laboratory molecular biology and single cell methods, bioinformatics and immunology. These include:
Project reference number: 982
|Rachael Bashford-Rogers||Wellcome Trust Centre for Human Genetics||Oxford University, Henry Wellcome Building of Genomic Medicine||GBRfirstname.lastname@example.org|
|Professor John A Todd FRS FMedSci||Wellcome Trust Centre for Human Genetics||Oxford University, Henry Wellcome Building of Genomic Medicine||GBRemail@example.com|
There are no publications listed for this DPhil project.